Overview

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
R-Pharm
Treatments:
Epothilones